STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the	Pg 2,
		title or the abstract	Abstract
		(b) Provide in the abstract an informative and balanced summary of	Pg 2,
		what was done and what was found	Abstract
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation	Pgs 3-4
		being reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	Pg 4
Methods			
Study design	4	Present key elements of study design early in the paper	Pg 5
Setting	5	Describe the setting, locations, and relevant dates, including periods	Pg 5
		of recruitment, exposure, follow-up, and data collection	
Participants	6	(a) Give the eligibility criteria, and the sources and methods of	Pg 5
		selection of participants	
Variables	7	Clearly define all outcomes, exposures, predictors, potential	Pgs 5-7
		confounders, and effect modifiers. Give diagnostic criteria, if	
		applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of	Pgs 5-8
measurement		methods of assessment (measurement). Describe comparability of	
		assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	Pgs 6-7
Study size	10	Explain how the study size was arrived at	Pg 5; Pg 8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If	Pg 5; Pg 7
		applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control	Pg 7
		for confounding	
		(b) Describe any methods used to examine subgroups and	N/A
		interactions	
		(c) Explain how missing data were addressed	Pg 7
		(d) If applicable, describe analytical methods taking account of	Pg 7
		sampling strategy	
		(e) Describe any sensitivity analyses	Pgs 6-7
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg	Pg 8
		numbers potentially eligible, examined for eligibility, confirmed	
		eligible, included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic,	Pg 8; 9-10
		clinical, social) and information on exposures and potential	Table 1
		confounders	1 4010 1
		(b) Indicate number of participants with missing data for each	Table 1
		variable of interest	1 4010 1
Outcome data	15*	Report numbers of outcome events or summary measures	Pg 9
Cateonic data	13	report numbers of outcome events of summary measures	157

16	(a) Give unadjusted estimates and, if applicable, confounder-	Pg 9;
	adjusted estimates and their precision (eg, 95% confidence	Table 1;
	interval). Make clear which confounders were adjusted for and why	Supl. Table
	they were included	4
	(b) Report category boundaries when continuous variables were	Table 2
	categorized	
	(c) If relevant, consider translating estimates of relative risk into	N/A
	absolute risk for a meaningful time period	
17	Report other analyses done—eg analyses of subgroups and	Pg 9-11
	interactions, and sensitivity analyses	
18	Summarise key results with reference to study objectives	Pg 12
19	Discuss limitations of the study, taking into account sources of	Pg 14-15
	potential bias or imprecision. Discuss both direction and magnitude	
	of any potential bias	
20	Give a cautious overall interpretation of results considering	Pgs 13-14
	objectives, limitations, multiplicity of analyses, results from similar	
	studies, and other relevant evidence	
21	Discuss the generalisability (external validity) of the study results	Pg 15
22	Give the source of funding and the role of the funders for the	Pg 16
	present study and, if applicable, for the original study on which the	
	present article is based	
	17 18 19 20 21	adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses 18 Summarise key results with reference to study objectives 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence 21 Discuss the generalisability (external validity) of the study results 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the

^{*}Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.